As Biohaven Pharma comes off a rollercoaster pipeline year, its CEO will take on more responsibility in a full C-suite makeover. Vlad Coric was unanimously elected to the role of chairman of the board…
Novartis is looking to milk one of its most prized possessions a little while longer without any generic competition, mostly because of a newly approved use that the Big Pharma won earlier this year…
An Italian pharma company engineered a nearly $850 million buyout last week looking to expand its rare disease portfolio and further soak up parts of the US market, but questions remain over the drugs…
Falling way behind the frontrunners in delivering a Covid-19 vaccine, French biotech Valneva has placed high hopes on boosters. Which may be why it is reacting strongly to a study suggesting that its…
Two lots of the Covid-19 treatment Veklury have been recalled by Gilead, the company said last week, after the appearance of glass particulates. A customer complaint was confirmed by Gilead’s…
All through this year you could practically feel the frustration of the biotech investor class as M&A activity continued to drag behind expectations — or desires. Buyouts of public companies provide…
Good morning and welcome back! Please join us at 2pm ET tomorrow for Women in Biopharma R&D — it’s our second annual event where you’ll meet 20 top women leaders shaping drug development today. It’s…
On the hunt for the next generation of
The FDA on Monday offered an overwhelmingly negative opinion on Reata Pharmaceuticals’ potential drug to slow the loss of kidney function in those with the rare disease Alport syndrome, according to…
The biotech sector has been booming throughout the Covid-19 pandemic — and while it has slowed down considerably, there are yet more SPACs at work. Blank check company BioPlus Acquisition Corp…
